International urology and nephrology
SGLT2 inhibitors and their role in reducing adiposopathy and inflammation in diabetes and non-diabetes CKD patients.
Ana Checa-Ros, Owahabanun Joshua Okojie, Nelia Steib, Antonio Bellasi, Pilar Salvador-Martínez, Isabel Fortea, Luis D'Marco
Published: 202510.1007/s11255-025-04965-6
Abstract
AIMS: This study aims to evaluate differences in adiposopathy and specific inflammatory biomarkers between type 2 diabetes mellitus (T2DM) and non-T2DM patients across various stages of chronic kidney disease (CKD). In addition, it explores potential…
Preview only. Read the full abstract at the source